This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Digging into the clinical landscape of Type 2 Diabetes and the potential of Novo Nordisk's once weekly insulin Icodec
Ticker(s): NVOWho's the expert?
Institution: PPD
- Medical Director at PPD; Former Associate Professor at the University of Nebraska Medical Center (UNMC) at Omaha
- Fellowship trained in Diabetes, Endocrinology, and Metabolism and specializes in preventing, diagnosing, and treating diseases related to hormone imbalance, and the bodys glands in the endocrine system
- Has authored or coauthored several peer-reviewed articles
- Manages 325 patients with Diabetes
Interview GoalThis conversation will focus on discussing the current standard of care and landscape of Type 2 diabetes in light of the recent results from the ONWARDS 5 phase 3a trial with once weekly insulin icodec
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
